Published in Hematology Week, March 31st, 2008
Paul Friedman, M.D., Incyte's President and CEO, stated, "We had a successful meeting with the FDA where we discussed the design of the registration studies of INCB18424 for myelofibrosis. We've reached agreement on the type of endpoints that will support approval and we will not be required to demonstrate improved survival or normalization of cell counts in the blood or bone marrow. Based on the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.